Dipyrone (oral)
Cautions
Contraindications
- Hypersensitivity to the active ingredient or any of its excipients
- Hypersensitivity to aspirin or other non-steroidal anti-inflammatory drugs
- First trimester and last 6 weeks of pregnancy
- Blood dyscrasias
- Bone marrow suppression
Cautions
- Second trimester and first 6 weeks of third trimester
- Breastfeeding
- Renal impairment
- Hepatic impairment
- Elderly
- Cardiac diseases
- Glucose 6 phosphatase dehydrogenase deficiency
- History of gastrointestinal ulceration, bleeding, or perforation
- Pre-existing infection
- Porphyria
Special populations
Pregnancy
- Caution: second and first 6 weeks of third trimester
- Contraindicated: First trimester and last 6 weeks of third trimester
- Dipyrone crosses the placenta. It is contraindicated during the first three months and the last six weeks of pregnancy
- Use during the other periods of pregnancy should be guided by an assessment of the benefit-risk profile, that is, the benefit of treatment to the mother should outweigh any potential risks to the mother or the foetus
Breastfeeding
- Caution; not recommended
- Dipyrone and its metabolites are excreted in breast milk and infants may be exposed to rather large amounts. Avoid use during breastfeeding and consider safer alternatives
- Breastfeeding should be avoided within 48 hours of maternal administration
Renal Impairment
- Caution; no dose adjustment recommended
Consider safer alternatives, as the benefit-risk ratio may be unfavourable
Hepatic Impairment
- Caution; no dose adjustment recommended
Consider safer alternatives, as the benefit-risk ratio may be unfavourable
Elderly
Adverse reactions
Central Nervous System Disorders
- Seizures
Cardiovascular Disorders
- Hypotension
Respiratory Disorders
- Bronchospasm
Gastrointestinal Disorders
- Nausea and vomiting
Genitourinary Disorders
- Acute kidney injury
- Interstitial nephropathy
Endocrine and Metabolic Disorders
- Loss of appetite
Skin and Subcutaneous Tissue Disorders
- Allergic skin rash
Immune, Blood and Lymphatic System Disorders
- Anaphylactic reactions
- Agranulocytosis
- Haemolytic anaemia
- Aplastic anaemia
Interactions
- Antiplatelets
- Anticoagulants
- Amiloride
- Thiazides
- Amitriptyline
Mechanism of action
Dipyrone (metamizole) is pyrazolone nonsteroidal anti-inflammatory agent. It is a sodium sulfonate derivative of aminopyrine. It has anti-inflammatory, antispasmodic, analgesic, antipyretic and anti-platelet effects.
Dosage forms
- Other
References
1. https://drive.google.com/drive/u/0/folders/0B-3fPTkNLWMsZlptQmxDMWxUTmc 2. Pharmacologist: Dr Ahmed Abulfathi [https://drive.google.com/drive/u/0/folders/1FjAUWV6vm6VrFIq6QPCnGkzCkU_wgUn8] 2.1 Frolich JC et al. Agents Actions Suppl 1986 2.2 Metamizole package insert 2.3 Arellano F et al. Eur J Clin Pharmacol 1990 2.4 Bar-Oz B et al. Drug Saf. 2003 2.5 Rizzoni G et al. Human Toxicol. 1984 3. NAPOS The Drug Database for Acute Porphyria: N02BB02 Metamizole; Accessed online 18 Feb 2019 [http://www.drugs-porphyria.org/languages/UnitedKingdom/s3.php?atc_code=N02BB02&l=gbr] 4. South African Institute for Drug-Free Sport; Dipyrone; Accessed online 18 Feb 2019 http://www.drugfreesport.org.za/online-medication-check
Medical aid coverage
data not yet integrated- Comprehensive Series—
- Executive Plan—
- KeyCare Series—
- Priority Series—
- Saver Series—
Formulary scraper pending — coverage tier, co-pay and authorisation requirements will appear here once data is ingested.
- BonClassic—
- BonComprehensive—
- BonEssential—
- BonFit Select—
- BonSave—
- BonStart—
Formulary scraper pending — coverage tier, co-pay and authorisation requirements will appear here once data is ingested.
- Beryl—
- Emerald—
- Onyx—
- Ruby—
- Sapphire—
- Tanzanite One—
Formulary scraper pending — coverage tier, co-pay and authorisation requirements will appear here once data is ingested.
- Aquarium Option—
- Efficiency Option—
- Marine Option—
Formulary scraper pending — coverage tier, co-pay and authorisation requirements will appear here once data is ingested.